<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Oncol</journal-id><journal-id journal-id-type="publisher-id">JO</journal-id><journal-title>Journal of Oncology</journal-title><issn pub-type="ppub">1687-8450</issn><issn pub-type="epub">1687-8469</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19259336</article-id><article-id pub-id-type="pmc">2648641</article-id><article-id pub-id-type="doi">10.1155/2008/942618</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Reinduction of Bevacizumab in Combination with Pegylated Liposomal Doxorubicin  in a Patient with Recurrent Glioblastoma Multiforme Who Progressed on Bevacizumab/Irinotecan</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Almubarak</surname><given-names>Mohammed</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Newton</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Altaha</surname><given-names>Ramin</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Section of Hematology/Oncology, Mary Babb Randolph Cancer Center, West Virginia University Hospital, Morgantown, WV 26506, USA</aff><aff id="I2"><sup>2</sup>School of Pharmacy, West Virginia University, Morgantown, WV 26506, USA</aff><author-notes><corresp id="cor1">*Ramin Altaha: <email>raltaha@hsc.wvu.edu</email></corresp><fn fn-type="other"><p>Recommended by Minesh Mehta</p></fn></author-notes><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>2</day><month>9</month><year>2008</year></pub-date><volume>2008</volume><elocation-id>942618</elocation-id><history><date date-type="received"><day>5</day><month>6</month><year>2008</year></date><date date-type="accepted"><day>5</day><month>8</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Mohammed Almubarak et al.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>Glioblastoma multiforme (GBM) carries a dismal prognosis despite the current standard of multimodality treatments. Recent studies showed promising results to a regimen consisting of a VEGF inhibitor, (bevacizumab) and a topoisomerase I inhibitor (irinotecan) [BI] in recurrent GBM. However, those patients with GBM who progress on BI will succumb to their disease generally in a very short period of time. We report a case of a 56-year-old male patient with GBM who declined surgical resection and received chemoradiation with temozolomide. This treatment was withheld secondary to significant thrombocytopenia. Subsequently, he achieved stable disease for 10 months with a regimen consisting of thalidomide and tamoxifen before progressing. This was followed by bevacizumab with irinotecan [BI], for which he had a significant partial response for 8 months with subsequent progression. Reinducing the patient with bevacizumab in combination with a pegylated liposomal doxorubicin [PLD] (a topoisomerase II inhibitor) demonstrated antitumor activity with significant shrinkage of contrast enhancing mass and peritumoral edema.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. Introduction</title><p>Glioblastomamultiforme (GBM) is the most common primary brain tumor in adults. Despite advancement in areas of clinical detectionand treatment, GBM continues to have an ominous prognosis with median survivalless than a year [<xref ref-type="bibr" rid="B1">1</xref>].  Historically,GBM was treated with resection followed by radiation. The addition ofnitrosourea-based chemotherapy added a small survival benefit. The standard oftreatment was changed after Stupp et al. [<xref ref-type="bibr" rid="B2">2</xref>] demonstrated animprovement in survival by 2 months using temozolomide in combination withradiation compared to radiation alone.</p><p>Bevacizumabis a recombinant humanized monoclonal antibody that inhibits the biologicactivity of vascular endothelial growth factor (VEGF). GBM is a highlyvascularized tumor with a high expression of VEGF [<xref ref-type="bibr" rid="B3">3</xref>].  Bevacizumabhas shown promising results in a recent phase II clinical trial when combinedwith a topoisomerase I inhibitor, irinotecan, for the treatment of recurrentGBM  [<xref ref-type="bibr" rid="B4">4</xref>]. The antitumoractivity of bevacizumab containing regimens could be due to enhancedpermeability of the tumor vasculature which leads to improved penetration ofthe cytotoxic chemotherapy agents. We hypothesized that replacing irinotecan with another  cytotoxicchemotherapy agent with a differenet resistance profile may overcome theresistance to BI regimen.</p><p>PLD is aliposome-encapsulated dosage form of doxorubicin which works by intercalatinginto DNA resulting in inhibition of DNA synthesis. It also inhibitstopoisomerase II [<xref ref-type="bibr" rid="B5">5</xref>]. PLD has several potential advantages overstandard doxorubicin including longer circulatory half-life, more specificdelivery to tumor tissue and reduced cardiac toxicity [<xref ref-type="bibr" rid="B6">6</xref>]. Across-resistance between irinotecan and PLD to our knowledge has not beendescribed. Combining PLDwith bevacizumab might prove to be effective intreating GBM.</p></sec><sec sec-type="section" id="sec2"><title>2. Case Report</title><p>A 56-year-old healthy man presented in October 2004 with short-term memory deficit and a left-sided visual field defect. A magnetic resonance image (MRI) of the brain showed a large (5.7 cm  &#x000d7;  3.5 cm)  right occipitoparietal enhancing mass  with extension into the ventricular system and satellite metastases with associated  edema and mass effect. He underwent a stereotactic biopsy of the lesion that revealed  a diagnosis of GBM. The patient declined surgical resection. He received steroids and  was placed on levetiracetam (Keppra, UCB Inc., Smyrna, Ga, USA) for  seizure prophylaxis.</p><p>The patient was started on concomitant chemoradiotherapy per Stupp regimen consisting of temozolomide (Temodar, Schering Corporation, Kenilworth, NJ, USA) 75 mg/m<sup>2</sup> daily as well as radiation therapy (a total of 59.4 Gy). He had significant improvement in his neurological function with evidence of partial response on brain MRI. However, temozolomide had to be discontinued after 2 months secondary to severe thrombocytopenia. After completion of the radiation therapy, he was then started on thalidomide 300 mg and tamoxifen 200 mg daily for maintenance. His disease was stable on this regimen for approximately 10 months. Subsequently, a brain MRI showed progression of disease. This regimen was discontinued and he was started on bevacizumab (Avastin, Genentech Inc., South San Francisco, Calif, USA) 10 mg/kg with  irinotecan 125 mg/m<sup>2</sup> every 2 weeks based on an abstract published  by Stark-Vance in 2005 [<xref ref-type="bibr" rid="B7">7</xref>].  He had a 90 percent decrease in the  tumor size after two cycles on this regimen. However, after seven cycles on this  regimen a brain MRI showed increased mass effect and interval development of abnormal  contrast enhancement in the medial hemispheric aspect of the right occipital and parietal  lobe area, compatible with progression of disease  (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><p>Subsequently, he was restarted on temozolomide 150 mg/m<sup>2</sup>  on days 1&#x02013;5 every month. He developed neutropenia requiring growth factor support as well as thrombocytopenia requiring oprelvekin (Neumega, Wyeth Pharmaceuticals Inc., Philadelphia , Pa). After 2 cycles on this regimen, his follow-up brain MRI showed progression of disease (<xref ref-type="fig" rid="fig2">Figure 2</xref>). He was not considered a candidate for additional alkylating agent-based chemotherapy such as carmustine (BCNU) or the PCV regimen (procarbazine, lomustine, vincristine) due to dose limiting hematologic toxicity experienced with temozolomide.</p><p>The patient was reinduced with bevacizumab 10 mg/kg with the addition of pegylated liposomal doxorubicin (Doxil, Ortho Biotech Products, LP, Bridgewater, NJ, USA) 20 mg/m<sup>2</sup> every 2 weeks.  His brain MRI (T1 with gadolinium, FLAIR and T2 weighted images) after 4 treatments showed substantial decrease in bulk of the large mass in the right posterior cerebral hemisphere with associated decrease in edema (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><p>Despite achieving the dramatic imaging response and initial improvement in performance status, the patient declined further chemotherapy and imaging modalities. He developed decubitus ulcer and died 2 months after he received his last dose of PLD/bevacizumab.</p><p>				<xref ref-type="table" rid="tab1">Table 1</xref> summarizes the treatment regimens and duration of response for this patient.</p></sec><sec sec-type="section" id="sec3"><title>3. Discussion</title><p>GBM is a highlyvascularized tumor and thus targeting angiogenesis could represent a major newtreatment approach. Ahmed et al. demonstrated 64% (or 9 out of 14 patients) response/disease stabilization lasting anywhere from8 to 135 weeks using an outpatient oral regimen of the angiogenesis inhibitor,thalidomide, plus tamoxifen, and temozolomide [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>VEGF inhibitors arecurrently being investigated in several clinical trials.  An abstract published by Stark-Vance at thesixth meeting of the European Association of Neuro-oncology showed 43% response(9 out of 21 patients) to a regimen consisting of bevacizumab and irinotecanevery 2 weeks [<xref ref-type="bibr" rid="B7">7</xref>]. Vredenburgh et al. further confirmed the efficacy of irinotecan andbevacizumab in patients with recurrent grade III-IV gliomas. In this phase IItrial, 57% out of the 35 patients had radiographic response and the 6-month overallsurvival was 77%. Of note, four patients developed thomboembolic complicationsand one had a CNS bleed [<xref ref-type="bibr" rid="B4">4</xref>]. Basedon this data, the National Cancer Comprehensive Network (NCCN) has updatedtheir guidelines recently to include bevacizumab-based regimens as a salvagetreatment option in recurrent GBM [<xref ref-type="bibr" rid="B9">9</xref>]. </p><p>Since VEGFinhibitors affect the vascular permeability of the tumor, this may result indecrease in contrast enhancement in MRI images [<xref ref-type="bibr" rid="B10">10</xref>]. This might lead to questioning the truevalidity of using MRI to assess response to treatment.  Pope et al. evaluated MRI response in high-gradegliomas treated with bevacizumab in addition to different chemotherapeuticagents. They noted reduction in contrast enhancing tumor in 7 out of 14patients in as little as 2 weeks. Of interest, even in those patients who didnot have reduction in tumors size, a reduction in edema was noted[<xref ref-type="bibr" rid="B3">3</xref>].</p><p>Nonetheless,response to such bevacizumab containing regimen in high-grade gliomas wasproved using positron emission tomography (PET) by Chen et al. In this study, a47% response rate (9 out of 19) was reported with 65% 6-month survival. Metabolic responders survived three times as long as nonresponders (10.8 versus3.4 months). This was the first study to describe the ability to use PET scanas an imaging modality for predicting survival in patients who were treatedwith bevacizumab [<xref ref-type="bibr" rid="B11">11</xref>]. </p><p>Irinotecan is awater soluble camptothecin (CPT) analog that interferes with the catalyticcycle of topoisomerase I enzyme. Irinotecanas a single agent has very low response rate in GBM [<xref ref-type="bibr" rid="B12">12</xref>]. Thesignificant response noted when combined with bevacizumab could be due toimproved drug delivery resulting from a reduction in interstitial fluidpressure and normalization of the tumor vasculature by bevacizumab [<xref ref-type="bibr" rid="B13">13</xref>]. This introduces the possibility of enhancedblood brain barrier (BBB) penetration of other cytotoxic agents when combinedwith bevacizumab.</p><p>Doxorubicin hasshown significant in vitro cytotoxicity in cell lines derived frommalignant glioma cells [<xref ref-type="bibr" rid="B14">14</xref>]. Unfortunately, doxorubicin does notadequately penetrate the BBB [<xref ref-type="bibr" rid="B15">15</xref>] and is subject to resistance dueto P-glycoprotein mediated efflux [<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>]. However, pegylated liposomal doxorubicinselectively overcomes the BBB in the tumor areas, with accumulation more than10 fold higher in the tumor than in normal brain tissue [<xref ref-type="bibr" rid="B18">18</xref>]. Pegylated liposomal doxorubicin alsoappears to overcome P-glycoprotein mediated resistance [<xref ref-type="bibr" rid="B19">19</xref>]. Moreover, there seems to be an enhanceddrug exposure and improvement in therapeutic activity when comparing pegylatedliposomal doxorubicin to conventional doxorubicin in brain tumors in rats [<xref ref-type="bibr" rid="B20">20</xref>].</p><p>A single agentregimen with pegylated liposomal doxorubicin has proven moderate efficacy inGBM patients as demonstrated by Fabel et al. who observed disease stabilizationin 7 of 13 patients (54%) treated with PLD 20 mg/m<sup>2</sup> every 2 weeks [<xref ref-type="bibr" rid="B21">21</xref>]. Similarly, Hau et al. observed 40% (out of 20 patients) overall responserate and 15% six months progression-free survival using PLD 20 mg/m<sup>2</sup> every 2weeks, either alone or with tamoxifen [<xref ref-type="bibr" rid="B22">22</xref>]. </p><p>In summary,previous studies demonstrated that pegylated liposomal doxorubicin penetratesBBB and achieves high-level concentration in tumor tissue. The recentlydescribed response to bevacizumab containing regimens opens the door forcombining bevacizumab with other cytotoxic chemotherapeutic agents. Theaddition of pegylated liposomal doxorubicin to bevacizumab seems to be areasonable alternative in recurrent GBM, as illustrated by the dramaticresponse observed in our patient despite heavy pretreatment. Further studiesare needed to evaluate this regimen as a therapeutic option for treatment ofrecurrent or refractory GBM.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reardon</surname><given-names>DA</given-names></name><name><surname>Wen</surname><given-names>PY</given-names></name></person-group><article-title>Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents</article-title><source><italic>Oncologist</italic></source><year>2006</year><volume>11</volume><issue>2</issue><fpage>152</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">16476836</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stupp</surname><given-names>R</given-names></name><name><surname>Mason</surname><given-names>WP</given-names></name><name><surname>van den Bent</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2005</year><volume>352</volume><issue>10</issue><fpage>987</fpage><lpage>996</lpage><pub-id pub-id-type="pmid">15758009</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pope</surname><given-names>WB</given-names></name><name><surname>Lai</surname><given-names>A</given-names></name><name><surname>Nghiemphu</surname><given-names>P</given-names></name><name><surname>Mischel</surname><given-names>P</given-names></name><name><surname>Cloughesy</surname><given-names>TF</given-names></name></person-group><article-title>MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy</article-title><source><italic>Neurology</italic></source><year>2006</year><volume>66</volume><issue>8</issue><fpage>1258</fpage><lpage>1260</lpage><pub-id pub-id-type="pmid">16636248</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vredenburgh</surname><given-names>JJ</given-names></name><name><surname>Desjardins</surname><given-names>A</given-names></name><name><surname>Herndon</surname><given-names>JE</given-names><suffix>II</suffix></name><etal/></person-group><article-title>Bevacizumab plus irinotecan in recurrent glioblastoma multiforme</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2007</year><volume>25</volume><issue>30</issue><fpage>4722</fpage><lpage>4729</lpage><pub-id pub-id-type="pmid">17947719</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gabizon</surname><given-names>AA</given-names></name></person-group><article-title>Liposomal anthracyclines</article-title><source><italic>Hematology/Oncology Clinics of North America</italic></source><year>1994</year><volume>8</volume><issue>2</issue><fpage>431</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">8040147</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>AM</given-names></name><name><surname>Yusuf</surname><given-names>SW</given-names></name><name><surname>Ewer</surname><given-names>MS</given-names></name></person-group><article-title>Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation</article-title><source><italic>International Journal of Nanomedicine</italic></source><year>2007</year><volume>2</volume><issue>4</issue><fpage>567</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">18203425</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stark-Vance</surname><given-names>V</given-names></name></person-group><article-title>Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma</article-title><source><italic>Neuro-Oncology</italic></source><year>2005</year><volume>7</volume><issue>3</issue><fpage>p. 369</fpage></citation></ref><ref id="B8"><label>8</label><citation citation-type="confproc"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Rabbani</surname><given-names>G</given-names></name></person-group><article-title>Phase II trial of thalidomide (TD), tamoxifen (TX), and temozolomide (T) for patients with advanced malignant gliomas (MG)</article-title><conf-name>In: Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO '05)</conf-name><conf-date>May 2005</conf-date><conf-loc>Orlando, Fla, USA</conf-loc></citation></ref><ref id="B9"><label>9</label><citation citation-type="other"><ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf">http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf</ext-link>.</citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gerstner</surname><given-names>ER</given-names></name><name><surname>Duda</surname><given-names>DG</given-names></name><name><surname>di Tomaso</surname><given-names>E</given-names></name><name><surname>Sorensen</surname><given-names>G</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name><name><surname>Batchelor</surname><given-names>TT</given-names></name></person-group><article-title>Antiangiogenic agents for the treatment of glioblastoma</article-title><source><italic>Expert Opinion on Investigational Drugs</italic></source><year>2007</year><volume>16</volume><issue>12</issue><fpage>1895</fpage><lpage>1908</lpage><pub-id pub-id-type="pmid">18041999</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Delaloye</surname><given-names>S</given-names></name><name><surname>Silverman</surname><given-names>DHS</given-names></name><etal/></person-group><article-title>Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2007</year><volume>25</volume><issue>30</issue><fpage>4714</fpage><lpage>4721</lpage><pub-id pub-id-type="pmid">17947718</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prados</surname><given-names>MD</given-names></name><name><surname>Lamborn</surname><given-names>K</given-names></name><name><surname>Yung</surname><given-names>WKA</given-names></name><etal/></person-group><article-title>A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study</article-title><source><italic>Neuro-Oncology</italic></source><year>2006</year><volume>8</volume><issue>2</issue><fpage>189</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">16533878</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><article-title>Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy</article-title><source><italic>Nature Medicine</italic></source><year>2001</year><volume>7</volume><issue>9</issue><fpage>987</fpage><lpage>989</lpage><pub-id pub-id-type="pmid">11533692</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>JEA</given-names></name><name><surname>Trilling</surname><given-names>T</given-names></name><name><surname>M&#x000f6;lenkamp</surname><given-names>G</given-names></name><name><surname>Egeler</surname><given-names>RM</given-names></name><name><surname>J&#x000fc;rgens</surname><given-names>H</given-names></name></person-group><article-title>Chemosensitivity of glioma cells in vitro: a meta analysis</article-title><source><italic>Journal of Cancer Research and Clinical Oncology</italic></source><year>1999</year><volume>125</volume><issue>8-9</issue><fpage>481</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">10480340</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neuwelt</surname><given-names>EA</given-names></name><name><surname>Pagel</surname><given-names>M</given-names></name><name><surname>Barnett</surname><given-names>P</given-names></name><name><surname>Glassberg</surname><given-names>M</given-names></name><name><surname>Frenkel</surname><given-names>EP</given-names></name></person-group><article-title>Pharmacology and toxicity of intracarotid adriamycin administration following osmotic blood-brain barrier modification</article-title><source><italic>Cancer Research</italic></source><year>1981</year><volume>41</volume><issue>11, part 1</issue><fpage>4466</fpage><lpage>4470</lpage><pub-id pub-id-type="pmid">6796261</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stan</surname><given-names>AC</given-names></name><name><surname>Casares</surname><given-names>S</given-names></name><name><surname>Radu</surname><given-names>D</given-names></name><name><surname>Walter</surname><given-names>GF</given-names></name><name><surname>Brumeanu</surname><given-names>T-D</given-names></name></person-group><article-title>Doxorubicin-induced cell death in highly invasive human gliomas</article-title><source><italic>Anticancer Research</italic></source><year>1999</year><volume>19</volume><issue>2A</issue><fpage>941</fpage><lpage>950</lpage><pub-id pub-id-type="pmid">10368637</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schott</surname><given-names>B</given-names></name><name><surname>Bennis</surname><given-names>S</given-names></name><name><surname>Pourquier</surname><given-names>P</given-names></name><name><surname>Ries</surname><given-names>C</given-names></name><name><surname>Londos-Gagliardi</surname><given-names>D</given-names></name><name><surname>Robert</surname><given-names>J</given-names></name></person-group><article-title>Differential over-expression of <italic>mdr1</italic> genes in multidrug-resistant rat glioblastoma cell lines selected with doxorubicin or vincristine</article-title><source><italic>International Journal of Cancer</italic></source><year>1993</year><volume>55</volume><issue>1</issue><fpage>115</fpage><lpage>121</lpage></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koukourakis</surname><given-names>MI</given-names></name><name><surname>Koukouraki</surname><given-names>S</given-names></name><name><surname>Fezoulidis</surname><given-names>I</given-names></name><etal/></person-group><article-title>High intratumoural accumulation of stealth&#x02192; liposomal doxorubicin (Caelyx&#x02192;) in glioblastomas and in metastatic brain tumours</article-title><source><italic>British Journal of Cancer</italic></source><year>2000</year><volume>83</volume><issue>10</issue><fpage>1281</fpage><lpage>1286</lpage><pub-id pub-id-type="pmid">11044350</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>L</given-names></name><name><surname>Jardillier</surname><given-names>J-C</given-names></name><name><surname>Malarska</surname><given-names>A</given-names></name><name><surname>Akeli</surname><given-names>M-G</given-names></name></person-group><article-title>Increased accumulation of drugs in multidrug-resistant cells induced by liposomes</article-title><source><italic>Cancer Research</italic></source><year>1992</year><volume>52</volume><issue>11</issue><fpage>3241</fpage><lpage>3245</lpage><pub-id pub-id-type="pmid">1591733</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siegal</surname><given-names>T</given-names></name><name><surname>Horowitz</surname><given-names>A</given-names></name><name><surname>Gabizon</surname><given-names>A</given-names></name></person-group><article-title>Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy</article-title><source><italic>Journal of Neurosurgery</italic></source><year>1995</year><volume>83</volume><issue>6</issue><fpage>1029</fpage><lpage>1037</lpage><pub-id pub-id-type="pmid">7490617</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fabel</surname><given-names>K</given-names></name><name><surname>Dietrich</surname><given-names>J</given-names></name><name><surname>Hau</surname><given-names>P</given-names></name><etal/></person-group><article-title>Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin</article-title><source><italic>Cancer</italic></source><year>2001</year><volume>92</volume><issue>7</issue><fpage>1936</fpage><lpage>1942</lpage><pub-id pub-id-type="pmid">11745268</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hau</surname><given-names>P</given-names></name><name><surname>Fabel</surname><given-names>K</given-names></name><name><surname>Baumgart</surname><given-names>U</given-names></name><etal/></person-group><article-title>Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma</article-title><source><italic>Cancer</italic></source><year>2004</year><volume>100</volume><issue>6</issue><fpage>1199</fpage><lpage>1207</lpage><pub-id pub-id-type="pmid">15022287</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1" position="float"><label>Figure 1</label><caption><p>MRI brain T1 with gadoliniumafter stopping bevacizumab with irinotecan.</p></caption><graphic xlink:href="JO2008-942618.001"/></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Brain T1 with gadoliniumprior to reinduction with bevacizumab with PLD.</p></caption><graphic xlink:href="JO2008-942618.002"/></fig><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Brain T1 with gadoliniumafter treatment with bevacizumab with PLD.</p></caption><graphic xlink:href="JO2008-942618.003"/></fig><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Summary of treatment regimens and duration of response. </p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"> Chemotherapy/treatment </th><th align="left" rowspan="1" colspan="1"> Response </th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">(1)  Temozolomide and radiation</td><td align="left" rowspan="1" colspan="1">Partial response after two months, but discontinued secondary to significant thrombocytopenia.</td></tr><tr><td align="left" rowspan="1" colspan="1">(2) Thalidomide and tamoxifen</td><td align="left" rowspan="1" colspan="1">Disease stabilization for 10 months with subsequent progression.</td></tr><tr><td align="left" rowspan="1" colspan="1">(3)  Bevacizumab with irinotecan</td><td align="left" rowspan="1" colspan="1">Significant partial response for 8 months with subsequent progression.</td></tr><tr><td align="left" rowspan="1" colspan="1">(4) Temozolomide reinduction</td><td align="left" rowspan="1" colspan="1">Disease progression after 2 months.</td></tr><tr><td align="left" rowspan="1" colspan="1">(5)  Bevacizumab reinduction and pegylated liposomal doxorubicin</td><td align="left" rowspan="1" colspan="1">Partial response (approximately 60%) after 2 months. Treatment stopped at the patient's request.</td></tr></tbody></table></table-wrap></floats-wrap></article>